TherapeuticsMD (NASDAQ:TXMD) upgraded by Zacks Investment Research to hold


TherapeuticsMD (NASDAQ:TXMD – Get a review) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report released Thursday, Zacks.com reports.

According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription, and over-the-counter products exclusively for women. It is developing three advanced hormone replacement products designed to alleviate symptoms and reduce health risks resulting from hormone deficiencies related to menopause. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “

Several other equity research analysts also commented on TXMD. Cantor Fitzgerald downgraded shares of TherapeuticsMD from an “overweight” rating to a “neutral” rating in a Friday, May 6 research report. HC Wainwright cut its price target on TherapeuticsMD shares from $150.00 to $125.00 and set a “buy” rating on the stock in a research report on Friday, March 11.

Shares of NASDAQ TXMD traded down $0.09 during Thursday’s trading, hitting $2.09. 7,226 shares of the company were traded, against an average volume of 479,480. The company has a market capitalization of $18.12 million, a price-earnings ratio of -0.09 and a beta of 2.09. TherapeuticsMD has a 1 year minimum of $2.05 and a 1 year maximum of $69.50. The company’s fifty-day moving average price is $12.14 and its 200-day moving average price is $16.74.

TherapeuticsMD (NASDAQ:TXMD – Get Rating) last reported results on Monday, May 16. The company reported ($5.69) EPS for the quarter, missing the ($3.50) consensus estimate of ($2.19). During the same period of the previous year, the company posted EPS ($5.50). As a group, sell-side analysts expect TherapeuticsMD to post year-to-date earnings per share of -10.27.

Several institutional investors have recently increased or reduced their stake in TXMD. The Healthcare of Ontario Pension Plan Trust Fund purchased a new equity stake in TherapeuticsMD in Q1 for approximately $1,309,000. Morgan Stanley increased its stake in TherapeuticsMD by 39.4% in the second quarter. Morgan Stanley now owns 10,203,011 shares of the company valued at $12,142,000 after buying an additional 2,882,996 shares in the last quarter. Rubric Capital Management LP increased its stake in Therapeutics® by 90.2% in Q3. Rubric Capital Management LP now owns 5,344,302 shares of the company valued at $3,962,000 after purchasing an additional 2,534,600 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Therapeutics® by 727.3% in Q1. Goldman Sachs Group Inc. now owns 2,860,361 shares of the company valued at $1,087,000 after purchasing an additional 2,514,618 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in TherapeuticsMD by 243.5% in the 1st quarter. Renaissance Technologies LLC now owns 3,147,599 shares of the company valued at $1,196,000 after purchasing an additional 2,231,301 shares in the last quarter. Institutional investors and hedge funds hold 33.91% of the company’s shares.

Company Profile TherapeuticsMD (Get a rating)

TherapeuticsMD, Inc operates as a women’s healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate to severe dyspareunia; BIJUVA, a bioidentical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate to severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.

Featured articles

Get a Free Copy of Zacks’ Research Report on TherapeuticsMD (TXMD)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com



Get news and reviews for TherapeuticsMD Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for TherapeuticsMD and related companies with MarketBeat.com’s FREE daily email newsletter.

Comments are closed.